---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070416"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:35:46.745981+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives

## Summary
- Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
- Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.
- Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.
- FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.
- TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed.

## SEC filing metadata
- accession: 0000950170-25-070416
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/0000950170-25-070416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/tpst-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070416
- JSON: https://secwatch.observer/filing/0000950170-25-070416.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.